MedTrace Logo

Wilate in Subjects With Von Willebrand Disease Who Undergo Surgery

NCT01365546 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2015-03-09

Study results available
· View outcomes & findings →

Summary

Proportion of surgeries in which the primary endpoint (overall assessment) is classified as success.

Conditions

  • Prevent Bleeding in Major Surgery

Interventions

BIOLOGICAL

human VWF/FVIII concentrate

intravenous infusion. Dose based on subject's individual invivo-recovery

Sponsors & Collaborators

  • Octapharma

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
6 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-06-30
Primary Completion
2014-02-28
Completion
2014-04-30

Countries

  • United States
  • Bulgaria
  • India
  • Italy
  • Oman
  • Poland
  • Romania
  • South Africa
  • Turkey (Türkiye)

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01365546 on ClinicalTrials.gov